Bluebird Bio reported $71K in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Agios Pharmaceuticals AGIO:US USD 3M 2.15M
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Amgen AMGN:US USD 5.06B 20M
Biogen BIIB:US USD 2.04B 66.1M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bluebird Bio BLUE:US USD 71K 297K
Gilead Sciences GILD:US USD 5.65B 829M
Intercept Pharmaceuticals ICPT:US USD 77.16M 5.72M
IONIS PHARMACEUT IONS:US USD 158.25M 29.21M
Moderna Inc MRNA:US USD 2.26B 1.1B
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Novartis NOVN:VX USD 9.18B 151M
Pfizer PFE:US USD 16.55B 2.52B
Ptc Therapeutics PTCT:US USD 203.12M 47.23M
Regeneron Pharmaceuticals REGN:US USD 2.62B 58.3M
Sarepta Therapeutics SRPT:US USD 190.32M 5.38M
Seattle Genetics SGEN:US USD 402.18M 10.78M
Ultragenyx Pharmaceutical RARE:US USD 82.07M 999K
Vertex Pharmaceuticals VRTX:US USD 2.04B 110.5M
YTE INCY:US USD 774.02M 92.14M